HIGHLIGHTS
- who: Adriana Celesia and colleagues from the Department of Biomedicine, Neurosciences and Advanced Diagnostics (BIND), Biochemistry Building, University of Palermo, Palermo, Italy have published the article: The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis, in the Journal: Biomedicines 2022, 1994 of 17/08/2022
- what: The authors focus on effects of pan-HDAC (Givinostat) in comparison with SAHA (Vorinostat) in melanoma cells bearing V600E mutation. The authors focused on the effects of ITF2357 on two BRAF V600E mutated cell lines, SK . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.